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Abstract: Current research suggests that alterations in neurodevelopmental processes, involving gene
X environment interactions during key stages of brain development (prenatal period and adolescence),
are a major risk for schizophrenia. First, epidemiological studies supporting a genetic contribution to
schizophrenia are presented in this article, including family, twin, and adoption studies. Then, an
extensive literature review on genetic disorders associated with schizophrenia is reviewed. These
epidemiological findings and clinical observations led researchers to conduct studies on genetic
associations in schizophrenia, and more specifically on genomics (CNV: copy-number variant, and
SNP: single nucleotide polymorphism). The main structural (CNV) and sequence (SNP) variants
found in individuals with schizophrenia are reported here. Evidence of genetic contributions to
schizophrenia and current knowledge on genetic syndromes associated with this psychiatric disorder
highlight the importance of a clinical genetic examination to detect minor physical anomalies in
individuals with ultra-high risk of schizophrenia. Several dysmorphic features have been described
in schizophrenia, especially in early onset schizophrenia, and can be viewed as neurodevelopmental
markers of vulnerability. Early detection of individuals with neurodevelopmental abnormalities
is a fundamental issue to develop prevention and diagnostic strategies, therapeutic intervention
and follow-up, and to ascertain better the underlying mechanisms involved in the pathophysiology
of schizophrenia.
Keywords: schizophrenia; clinical genetics; physical examination; dysmorphic features; morpho-
logical abnormalities; minor physical anomalies; early detection; neurodevelopmental disorder;
genetic disorders
1. Introduction
Schizophrenia is a chronic psychiatric disorder. The diagnosis, according to ICD-10
(World Health Organization-WHO) and DSM-5 (American Psychiatric Association) crite-
ria [1,2], is based on three main psychopathological dimensions: (1) delusional distortion
of reality with positive symptomatology; (2) affective impoverishment with negative symp-
tomatology including apathy and social withdrawal; and (3) disorganization of thought.
Schizophrenia affects 0.3 to 0.7% [1] of the world population (approximately
600,000 individuals in France) with typically adult-onset schizophrenia (AOS, at age ≥ 18 years).
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However, early onset schizophrenia (EOS, onset before age 18 years, prevalence of approx-
imately 0.03% [3]) and very early onset schizophrenia (VEOS, onset before age 13 years,
prevalence of approximately 0.002% [3,4]) are also observed.
Schizophrenia is viewed as a complex multifactorial disorder and is classified by
the WHO in the group of the 10 diseases that cause the most disability. Current research
suggests that alterations in neurodevelopmental processes, involving interactions between
genetic and environmental factors during key stages of brain development (prenatal period
and adolescence), are a major risk for schizophrenia [5]. Early detection of individuals with
neurodevelopmental abnormalities is therefore a fundamental issue. This would make
possible to identify homogeneous subgroups of patients with similar pathophysiological
pathways which is a key stage for the etiological understanding of this complex disease.
Many studies have described different phases of symptoms (behavioral and adjust-
ment problems) observed in almost half of patients with schizophrenia in the 10 years
preceding the first hospitalization [6]. They are based on Larsen’s work [7] which describes
three phases before the onset of the disease: (1) the pre-morbid phase in childhood or
preadolescence with certain signs of vulnerability: higher level of anxiety [8], cognitive
deficit, especially attention deficit [9], language delay and difficulty in social adjustment
with aggressive or disruptive behavior [10]; (2) the early prodromal phase a few years
before the first psychotic episode (up to 5 years before [11]) with nonspecific symptoms
and perceptual abnormalities: abnormal visual perception (notably for the size of objects
and their distance), change in social interactions (such as social withdrawal and isolation),
verbal language impairments (such as production of maladapted words or fading), other
cognitive impairments (such as feeling of thought blockage and attention deficit), and
motor impairments (automatic gesture abnormalities) [11,12]; (3) and the late prodromal
phase with the appearance of the first psychotic symptoms: hallucinations, disorganized
speech, negative symptoms [1].
The current priority is to develop earlier diagnostic strategies to enable better clinical
management and promote therapeutic interventions as soon as possible knowing that early
detection and treatment of schizophrenia can improve the prognosis [13,14]. Duration
of untreated psychosis (DUP) is also known to be an important prognosis factor for the
quality of the long-term therapeutic response. The subsequent course of the disease is less
favorable when the DUP is long [15]. The studies conducted to identify etiological factors
of schizophrenia are therefore essential to allow a diagnostic orientation and appropriate
early therapeutic strategies.
Neurodevelopment in humans concerns the establishment of the nervous system
during embryogenesis and the following stages of ontogeny. This term includes all the
processes that allow the initial development of the nervous system in utero to matu-
ration process during childhood and adolescence. The initial hypothesis in favor of a
neurodevelopmental origin of psychiatric disorders stems from the assumption that ab-
normalities occurring during windows of vulnerability of brain development may favor
the appearance of psychiatric disorders. These windows occur at multiple times during
development [16,17]. Early abnormal neurodevelopment (during embryogenesis) can lead
to dysplasia of certain neuronal circuits that may be responsible for the premorbid abnor-
malities observed in some patients with schizophrenia [18]. Furthermore, the onset of the
disease may be also linked to a later abnormal brain maturation during adolescence [19].
These abnormalities in brain development and maturation appear to be the result of in-
teractions between genetic and environmental factors that lead to cell proliferation and
migration defects, lack of synaptogenesis and myelination failure [20,21]. Patients with
mutations (de novo or inherited from a parent) in candidate genes for schizophrenia would
have a particular sensitivity to certain environmental factors. It may be the combination of
these genetic and environmental factors that would lead to the onset of the disease. The
candidate genes for schizophrenia are involved in several key stages of brain development
and their function is modulated by environmental factors [22]. If prenatal neurodevelop-
mental anomalies are involved in the etiopathology of schizophrenia, then the symptoms
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that appear during adolescence should no longer be considered as the beginning of the
disease but as an already evolved phase of disorder. From this postulate comes the concept
of ultra-high risk (UHR) of psychosis. Individuals with ultra-high risk of schizophrenia
have a genetic vulnerability to trigger the disease but symptoms of schizophrenia may
not express without exposure to certain environmental factors. From a clinical point of
view, this highlights the importance to follow these individuals earlier to propose preven-
tion strategies based on close monitoring and rapid therapeutic intervention [17,23]. To
develop such strategies, one must be able to identify early vulnerability factors. Markers of
early neurodevelopmental abnormalities, such as minor neurological and morphological
abnormalities, may play a major role in prevention strategies and early detection.
The ‘minor’ neurological abnormalities or soft signs have been of interest because their
presence may reflect high neurodevelopmental abnormalities. It is noteworthy that soft
signs are significantly associated with schizophrenia and not with other psychiatric disor-
ders. They must be distinguished from ‘major’ neurological signs that correspond to motor
or sensory abnormalities that may be related to dysfunction of a specific brain area. Several
studies [24,25] suggest that patients with schizophrenia have neuromotor signs called
‘minor’ neurological signs—such as coordination disorders, fine and gross motor skills,
and sensory integration disorders—even during the first episode. They are also present in
the parents of patients and are more frequent in familial schizophrenia [26], which explains
why they are proposed as endophenotypic markers for schizophrenia [27]. In addition,
it has recently been shown that soft signs are more common in EOS, before adolescence,
compared to AOS. EOS individuals have also significantly more soft signs than the general
population, particularly motor coordination disorders and laterality disorders [28]. These
signs could differentiate UHR individuals from typically developing individuals with an
accuracy of 85.9% [29]. These results suggest that soft signs could be viewed as markers of
a more prominent neurodevelopmental form [30]. Regarding these findings concerning
soft signs, it is hypothesized that minor morphological abnormalities would also be the
markers for early identification of UHR individuals. Minor morphological abnormalities
in schizophrenia would reflect underlying genetic factors and would represent objective,
early, and stable endophenotypic markers similarly as for soft signs [31–33].
The assumption that schizophrenia has neurodevelopmental origins requires studies
to identify genes involved in neurodevelopmental processes as vulnerability genes for
schizophrenia. These genetic studies need to direct research towards certain genetic
syndromes already known and for which the risk of developing schizophrenia is higher
than in the general population.
2. Epidemiological Studies Supporting a Genetic Contribution to Schizophrenia
Individuals with a parent with schizophrenia have a higher probability of developing
the disease. Sibling studies have shown that siblings of individuals with schizophrenia
have 6% risk of developing schizophrenia, 15% if they are dizygotic twins, and 50% if they
are monozygotic twins. The results of the studies on adopted children showed that 6%
of biological siblings adopted in a different family from their index case siblings develop
schizophrenia. Heritability is estimated between 79% [34] and 82–85% [35], based on a
non-Mendelian transmission profile.
2.1. Family Studies
Several epidemiological studies reveal a family aggregation of cases of schizophrenia,
which means that the closer a related individual is to a patient, the more likely this
individual is to develop schizophrenia over his or her lifespan, but the mode of transmission
does not correspond to a Mendelian monogenic transmission profile [36]. Gottesman and
Shields [37] have shown that, compared to the current risk of 1% in the general population,
the risk of schizophrenia is about ten times higher in the first-degree relatives of a patient
with schizophrenia. This risk is higher among siblings (10.1%) or children (12.8%) than
among parents (5.6%). These differences could be explained by the low rate of reproduction
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and marriage of patients with schizophrenia [38]. The risk of developing schizophrenia for
a child of two parents with schizophrenia is estimated at 46% [39]. Among second-level
relatives (uncles and aunts, nephews and nieces, and grandchildren), the risk of recurrence
of schizophrenia is about 3% and less than 2% for third-degree relatives. Maier et al. [40]
found a risk of recurrence of 5% for first-degree relatives, 3.1% for second-degree relatives
and 1.5% for third-degree relatives, compared with a risk of 0.8% for controls. The risk
of recurrence of the disease appears as a function of the genetic burden, reflected by the
number of subjects affected in the same family (almost 17% of recurrence, if a brother
and a parent are both affected), the proximity of the relationship with the proponent and
also the severity of the proponent’s clinical signs (about 21% recurrence in children of a
hebephrenic patient and about 10% in children of a paranoid patient) [41].
Close relatives of individuals with schizophrenia have also a high risk of develop-
ing personality disorders (paranoid, schizotypal) or psychiatric disorders (schizophrenia,
schizoaffective disorders, schizophreniform disorder, brief psychotic disorder, unspecified
psychotic disorder, unipolar depression), questioning the existence of genetic factors (such
as single nucleotide polymorphisms in core circadian clock genes) shared by these psychi-
atric disorders [42]. In addition, there are also some clinical features of schizophrenia, such
as age at onset, that may be influenced by family history. Gorwood et al. [43] conducted
studies in the French Reunion Island on individuals with schizophrenia (N = 663) divided
according to the presence or absence of another individual with schizophrenia among the
parents of the first and second degrees. The median age at onset differed according to
sex and gender: men were younger (mean age = 27.8 years) than women (31.5 years). A
comparison of age at onset based on family history revealed that the onset was later for
women with no family history than for the other three groups (men with or without family
history and women with family history). No difference appeared in the comparison of
early ages for men and women with family history. Svensson et al. [44] showed that family
aggregation of schizophrenia was reduced by higher age at onset. The authors created a
population cohort in Sweden with 5,075,998 siblings born between 1932 and 1990. Of this
cohort 16,346 cases of schizophrenia were identified. Family aggregation was measured
as the risk of sibling recurrence, defined as the risk of schizophrenia in biological siblings
of patients with schizophrenia compared to risk among siblings of unaffected subjects.
The authors found a significant lower recurrence risk ratio for siblings of later onset cases
(7.2, 95%, CI: 6.7–7.9) compared to early onset cases (10.8, 95%, CI: 9.4–12.2). Kallmann
and Roth [45] compared the family history of cases of preadolescents with schizophrenia
(52 twins and 50 singles younger than 15 years) with those of a comparable adult sample
(691 twins index cases) and observed no significant differences between groups regarding
the twin concordance rates or the schizophrenia rates for the parents (12.5% and 9.2%) and
siblings (12.2% and 14.3%) of index cases. Fathers and mothers contribute equally to the
rate of parental schizophrenia, whereas mono and dizygotic twins of schizophrenic index
cases differ as much in concordance for schizophrenia in preadolescents (17.1% and 70.6%)
as for schizophrenia in adults (14.7% and 85.8%). For the authors, these results indicate an
early effect in childhood schizophrenia of the same genotype supposed to be responsible
for the underlying symptoms of schizophrenia in adults [45]. The authors found a trend
towards increasing the number of early cases of schizophrenia among twins and brothers
of early index cases.
Finally, it is noteworthy that family studies do not allow the effects of genetic vulnera-
bility factors to be differentiated from the effects of environmental factors, strengthening
the need for twin and adoption studies.
2.2. Twin Studies
Cardno and Gottesman [46] found, based on several studies, that within monozygotic
twin pairs (monozygotic twins share an identical genotype), the concordance rate for
schizophrenia was ranged from 41% to 65% and from 0% to 28% in dizygotic twins
(dizygotic twins have a different genotype). Heritability has been estimated from 80% to
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85%. In their 2003 meta-analysis, Sullivan et al. [47] found heritability at 81% (95%, CI:
73–90%). Despite the heterogeneity of the results, the concordance rate appears always
higher in the monozygotic twins than in the dizygotic twins (see Table 1, [39,48–60]). This
observation should be taken with caution because this superiority of the concordance
rate in the monozygotic twins may be not only related to shared genetic factors but also
possibly to shared intra-uterine disturbances, more frequent in the monozygotic twins. The
fact that the concordance rate in monozygotic twins does not reach 100% suggests that
environmental factors may modulate the effects of genetic factors.
Table 1. Concordance rates for schizophrenia in monozygotic twins and dizygotic twins.
Monozygotic Dizygotic







Luxenberger, 1928 [48] 19 58 13 0
Rosanoff et al., 1934 [49] 41 61 53 13
Kallman, 1953 [50] 174 69 296 11
Slater and Shields, 1953 [51] 37 65 58 14
Inouye, 1963 [52] 58 59 20 15
Tienari, 1963 [53] 17 35 20 13
Kringlen, 1967 [54] 55 45 90 15
Fischer et al., 1969 [55] 25 36 45 17
Essen-Möller, 1970 [56] 11 64 27 15
Gottesman and Shields, 1972 [39] 22 58 33 12
Fischer, 1973 [57] 21 56 41 27
Kendler and Robinette, 1983 [58] 164 31 268 7
Onstad et al., 1991 [59] 24 48 28 4
Franzek and Beckmann, 1998 [60] 9 67 12 17
Comparing offspring of discordant monozygotic twins for schizophrenia, Kringlen
and Cramer [61] have shown that the risk of schizophrenic disorders in the offspring
of affected monozygotic twins is not significantly different from the risk in offspring of
non-affected monozygotic twins. According to Gottesman and Bertelsen [62], the risk
for schizophrenia among the descendants of monozygotic twins is very similar in the
14 children of schizophrenic identical twins (16.8%) and in the 24 children born from
non-schizophrenic twins (17.4%). These results suggest the existence of epigenetic and/or
environmental factors that are not shared.
2.3. Adoption Studies
Adoption studies help to separate the influence of genetic factors from environmen-
tal factors, such as studies of separately raised twins [63]. Slater and Cowie [64] found
concordance of 77.6% for monozygotic twins in separated lives and of 91.5% for those
raised together. In adoption studies the prevalence of schizophrenia was found to be
higher in adopted children with affected biological relatives than in adopted children
without affected biological relatives, both living in the same environment. From a sample
of 5483 subjects adopted early in life by unrelated people, Kety et al. [65] compared the
biological and adoptive relatives of 33 of these individuals who became schizophrenic
to 33 non-schizophrenic adoptees. They found that 9% of the biological relatives of indi-
viduals with schizophrenia had schizophrenia spectrum disorders compared with 2% of
the biological relatives of control subjects. Lichtenstein et al. [66] used Swedish registers
over several generations to study the risks of schizophrenia, bipolar disorder and their
comorbidity in biological and adoptive parents, descendants, siblings, and half-siblings of
patients. First-degree relatives with schizophrenia or bipolar disorder were at increased
risk for these disorders. Half-siblings had a considerably increased risk, but significantly
less than siblings. In the analysis of parents of individuals with bipolar disorder, there
was an increased risk of schizophrenia for all relationships, including adopted children
Int. J. Mol. Sci. 2021, 22, 9464 6 of 22
of biological parents with bipolar disorder. The authors conclude that schizophrenia and
bipolar disorder share common genetic factors. Higgins [67] compared two groups of
children born from mothers with schizophrenia, one raised by their biological mother and
the other one by an adoptive mother; they found that the risk of schizophrenia was the
same in both groups. These results suggest that the risk for schizophrenia depends more
on genetic factors than on environmental factors.
3. Genetic Disorders Associated with Schizophrenia
An extensive literature review was conducted to identify genetic disorders most
frequently associated with schizophrenia. The results are presented in Table 2 and dif-
ferentiate genetic disorders of chromosomal origin from those of monogenic origin. This
table includes only genetic syndromes involving a monogenic disorder or chromosomal
rearrangement, and thus does not include polygenic causes and genetic disorders related
to epigenetic mechanisms. The results are not exhaustive.
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The estimated rate of genetic disorders in the schizophrenia population and the es-
timated rate of schizophrenia in patients with the genetic mutation are provided when
the data are available. To examine the neurodevelopmental hypothesis, the age at onset of
schizophrenia (VEOS, EOS, AOS) was also indicated. The other possible associated psychi-
atric and psychological disorders as well as the morphological abnormalities characterizing
the genetic syndrome are detailed.
4. Genomics and Schizophrenia: Structural (CNV: Copy Number Variant) and
Sequence (SNP: Single Nucleotide Polymorphism) Variants
As we have seen, epidemiological data on twins and adopted children support a
significant role of genetic factors and the involvement of environmental events in the de-
velopment of the disease, suggesting that schizophrenia is a neurodevelopmental disorder.
These findings led researchers to conduct many studies on genetic associations to identify
risk factors for schizophrenia.
Very early-onset schizophrenia (VEOS) is rare (prevalence of approximately 0.002% [3,4]),
more severe (especially when VEOS is associated with catatonia [101]), and more fre-
quently associated with genetic factors than schizophrenia with later onset [102]. In 67%
of children with childhood-onset schizophrenia, premorbid motor as well as social and
language impairments were observed [103]. Individuals with a very high genetic risk
for schizophrenia are more frequently carriers of chromosomal rearrangements. Among
these rearrangements, the 22q11.2 deletion and (1:11) (q43, q21) translocation are the most
described in cytogenetic studies. The 22q11.2 deletion concerns 1.5 to 3 Mb—i.e., 30 to
40 genes [104]—particularly the COMT (Catechol-O-Methyltransferase) gene involved in
the degradation of neurotransmitters including dopamine [105]. This region is associated
with velocardiofacial syndrome (VCF), also known as DiGeorge syndrome, in which up to
30% of adults develop a psychotic spectrum disorder of schizophrenia. The translocation
between chromosome 1q and 11q affects the DISC (Disrupted in Schizophrenia) gene on
chromosome 1, which encodes a protein involved in neuronal migration and axonal growth.
This genetic abnormality is associated with a risk of developing schizophrenia [91].
Subsequently, many genetic studies have been developed to identify vulnerability
genes for schizophrenia. The first strategies were based on the search for candidate genes in
relation to the proposed hypotheses related to a neurobiological (dopaminergic, serotoniner-
gic, glutamatergic) or neurodevelopmental disorder [106]. The hypothesis of schizophrenia
as a neurobiological disorder has focused since the 1960s on presynaptic dopaminergic
dysfunction, and more precisely since the therapeutic effects of the first antipsychotics
were mainly observed for positive symptoms of schizophrenia due to their antagonistic
action on dopamine D2 receptors. Today, the dopaminergic neurobiological model devel-
ops around two excitation/inhibition imbalances in the cortical circuits: hyperactivity of
the mesolimbic dopaminergic neurons (sub-cortical) underlying the positive symptoms
(delusional ideas), and hypoactivity of the neurons mesocortical dopaminergic (prefrontal
cortex) underlying negative (blunted affect) and cognitive symptoms [107]. However, the
efficacy of antipsychotics in the control of deficit symptoms of schizophrenia (negative,
depressive, and cognitive symptoms) is negligible, and one-third of patients do not respond
to antipsychotic treatments [108], suggesting that schizophrenia is not exclusively due to a
primary dysfunction of the dopaminergic system.
The pharmacological approach has questioned associations between schizophrenia
and glutamate, which is the major excitatory neurotransmitter in the central nervous system
in mammals (40% of synapses). The interest of glutamatergic transmission in schizophrenia
arises initially from the observation of the effects of psychotomimetic drugs, phencyclidine
(PCP) and ketamine, which are noncompetitive NMDA glutamatergic receptor antagonists.
These drugs, at subanesthetic doses in healthy volunteers induce similar symptoms to
the ones observed in schizophrenia [109–111]. Notably, ketamine, which is a dissociative
anesthetic used in human and veterinary medicine since the 1970s, has the particular-
ity of inducing symptoms close to a first psychotic episode of schizophrenia, including
positive symptoms (perceptual illusions and distortions), negative signs (blunted affects
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and disorganization of thought), and cognitive disorders (impairments in immediate and
delayed recall, verbal fluency disorder, attention deficit disorder) [112]. Glutamate can act
on two major types of glutamatergic receptors: the postsynaptic iGluR ionotropic receptors,
ion-permeable ion channels (Na, K Ca), or the metabotropic mGluR receptors which are G
protein-coupled. The metabotropic mGluR receptors are subdivided into three groups: the
group I (mGluR 1 and 5) receptors are mainly postsynaptically coupled with phospholipase
C, whereas the group II (mGluR 2 and 3) and group III (mGluR 4; 7 and 8) receptors are
presynaptically coupled with adenylate cyclase [112,113]. There are three types of iGluR
receptors according to their pharmacological properties: NMDA (N-methyl-D-aspartate),
AMPA (Amino-3-hydroxy-5-methyl- 4-isoxazole propionic acid) and kainate. AMPA and
NMDA receptors are the major postsynaptic receptors. Activation of the NMDA receptor
requires the binding of D-serine to GluN1 subunits and glutamate to GluN2 subunits, to
induce channel opening at their center, calcium entry, and then a cascade of intracellular
signals. Consequently, the expression of several genes is modified which allows an acute
functional synaptic plasticity, and then a long term neural structural plasticity [114]. Excess
of glutamatergic stimulation can become toxic, triggering a massive influx of calcium into
neuronal cells, and lead to apoptotic cell death.
Binding assays are based on the systematic screening of genomes within the family
with affected individuals and then within a case/control population, with the aim of
establishing a significant association of polymorphisms with schizophrenia. Studies have
identified several candidate loci on different chromosomal regions that may be associated
with the risk of schizophrenia, including NOSAP1 (1q), RGS4 (1q), DNTBP1 (6p), NRG1
(8p), and G72/G30 (13q). The locus G72/G30 on chromosome 13 comprises the DAOA
gene, which encodes the D-Amino Acid Oxidase Activator, a protein responsible for the
oxidation of D-serine. D-serine is a mandatory co-agonist for the activation of synaptic
glutamatergic NMDA receptor. Astrocytes and glial brain cells have, in addition to a role
of architectural support, regulatory functions of transmission of information at the level
of the synapse. Astrocytes can capture D-serine catabolized by DAOA. The NRG1 gene
encoding Neuregulin-1 located on chromosome 8p is associated with a risk of schizophrenia.
It is a complex gene of 25 exons with alternative promoters and splicing, allowing the
production of multiple different proteins. Neuregulin-1 is involved in the formation of
glutamatergic neuronal dendritic spines, neuronal migration, Schwann cell growth, and
myelination [106]. The mutation in the NRG1 is expected to contribute to an increase in
neuregulin-1 signaling and thus to NMDA receptor hypofunction [115]. Since NMDA
receptors are involved in the excitation of GABAergic interneurons, a key regulator of
excitation, NMDA receptor hypofunction may induce a decrease in interneuron excitation
and thus a disinhibition of pyramidal cells [116]. The DTNBP1 gene encodes dysbindin,
a dystrophin-associated protein complex (DAPC) that plays a role in cognitive function
via the glutamatergic NMDA receptor [117]. KO mice for DTNBP1 have a behavioral
phenotype sharing similarities with schizophrenia, including cognitive dysfunction, as
well as impaired hippocampal long-term potentiation [118].
Linkage analyses have made it possible to establish genetic maps of schizophrenia
markers covering the entire genome, without identifying robust targets with the necessary
criteria of significance. Overall, the results of these genetic association studies have been dis-
appointing with many contradictory results that are difficult to reproduce, partly because of
insufficient sample sizes and therefore a lack of statistical power to meet the genome wide
significance level (5 × 10−8) [119]. Technological advances in high-throughput sequencing
(HTS) have provided the opportunity to analyze widely human genomes in case/control
populations. These large-scale genetic association studies have identified hundreds of thou-
sands of nucleotide polymorphisms (SNPs). SNPs are sequence variants and correspond to
genomic locations that may contain allelic differences. The GWAS (Genome-Wide Associa-
tion Studies) involved 113,075 control subjects and 36,989 individuals with schizophrenia,
enabling the identification of 108 independent sites on the genome associated with the
risk of schizophrenia with a significance threshold of 5 × 10−8 [119]. Among these loci,
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one is associated with the dopamine D2 receptor (DRD2) and several with glutamatergic
neurotransmission—such as mGlu3 (GRM3), GluN2A (GRIN2A), SR (SRR), and AMPAR
(GRIA1). Finally, some loci are associated with calcium signaling (CACNA1C, CACNB2,
and CACNA1l) [120]. The GRIN2A gene found among the 108 loci codes for the gluta-
matergic receptor GluN2A subunit. KO mice for GRIN2A exhibit similar behaviors to those
observed in animal models of schizophrenia [121]. Numerous data across the literature
suggest hypofunctioning of the glutamatergic system via NMDA receptor hypofunction
in schizophrenia [122]. The involvement of other receptors has also been explored, no-
tably AMPA receptors, during migration of GABA interneurons or in cognitive functions
(memory and attention). Similarly, metabotropic receptors of group II mGlu2/3 have been
studied; they are auto-receptors activated on astrocytes upon excessive glutamate release
into the synaptic cleft. This mechanism prevents neuronal excitotoxicity by maintaining a
sub-toxic level of glutamate and allows glutamate to be recycled [111]. These genes have
been investigated as a potential therapeutic target in schizophrenia such as the SRR gene
which codes for Serine Racemase [123–126].
It appears clearly that the effects of each SNP or sequence variant are low (odds ratio < 1.1),
explaining the need for large studies to obtain satisfactory statistical power. Newer mi-
croarray technologies have also detected structural polymorphic variants in which DNA
segments of the genome are deleted or duplicated in multiple copies, called Copy Number
Variants (CNVs). These variants appear to be associated more frequently with sporadic
cases than cases of familial schizophrenia. In addition, they appear to have greater effects
than SNPs on the risk of schizophrenia. The first genotype analysis of schizophrenia
susceptibility loci analyzed 38,779 individuals with microarray to find the presence of
CNV. They identified 1035 individuals with copy number variants of recurrent loci: 1q21.1,
15q11.2, 15q13.3, 16p11.2, 16p13.11, and 22q11.2. Sahoo et al. [127] concluded that the
phenotypic effects of copy number variants associated with schizophrenia are pleiotropic
and imply the existence of shared biologic pathways.
An analysis of 21,094 patients with schizophrenia and 20,227 control individuals found
8 CNVs with a highly significant association (odds ratio of 0.15 to 67.7), with deletions
1q21.1, 2p16.3, 3q29, 15q13.3, 16p11.2, and 22q11.2, as well as duplications 7q11.23 and
16p11.2 [128]. It is noteworthy that 2.5% of the patients and 0.9% of the controls carried one
of these CNVs. Whereas most CNVs associated with schizophrenia encompass multiple
genes, the deletion of chromosome 2p16.3 specifically affects the NRXN1 gene encoding
the synaptic cell adhesion molecule, neurexin-1, which is involved in the regulation of
synaptic development and in synaptic transmission [129–131]. Concerning Sahoo et al. and
Marshall et al.’s findings [127,128] of CNVs associated with schizophrenia, several authors
have confirmed these results and more details are described below in this article for the
following loci: 1q21.1, 3q29, 7q11.23, 22q11.2, 15q11.2, and 16p11.2. The duplication of
the chromosome 1q21.1 region (approximately 1.35-Mb) was reported in individuals with
schizophrenia and tetralogy of Fallot, and the reciprocal deletion was also identified [93–95].
The morphological abnormalities observed in this genetic disorder are detailed in Table 2.
Mulle et al. [132] identified a region in chromosome 3q29 involving CNV significantly
associated with schizophrenia. The microdeletion of the chromosome 3q29 region (approx-
imately 1.5 Mb) contain 22 genes, including PAK2 and DLG1, which may play a putative
role in the psychiatric manifestations of the 3q29 deletion syndrome. Mulle et al. [132]
reported a 1.4 megabase duplication on the chromosome 7 (7q11.23) that increases the risk
for schizophrenia over 10 times. A reciprocal 7q11.23 duplication was also observed in
schizophrenia by Kirov et al. [85]. It is noteworthy that the 7q11.23 deletion corresponds
to the Williams–Beuren syndrome, a multisystem neurodevelopmental disorder reported
to be associated with autism and including speech delay, craniofacial anomalies, and
increased incidence of congenital anomalies (for a review, see Tordjman et al. [133–135]).
Mervis et al. [136] found that patients with reciprocal 7q11.23 duplication syndrome had
significantly higher levels of separation anxiety compared to patients with Williams–Beuren
syndrome and to the general population, which could be of interest regarding anxiety prob-
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lems reported often in patients with schizophrenia [137]. The 22q11.2 deletion syndrome
appears to be a recurrent genomic disorder distinct in fact from DiGeorge syndrome (DGS)
and velocardiofacial syndrome (VCFS). About 97% of patients with DGS/VCFS have a
common recurrent 3-Mb deletion of the 22q11 region [138]. Vassos et al. [72] who was the
first to estimate the penetrance for schizophrenia of several CNVs, found modest rates of
penetrance for all of them, except for the 22q11.2 deletion in the VCFS region which had a
much higher penetrance of 55%. The deleted region of chromosome 15q11.2 is on approx-
imately 500 kb of the Prader-Willi/Angelman syndrome critical region [79]. This region
includes four genes, TUBGCP5, NIPA1, NIPA2, and CYFIP1. The deletion of chromosome
15q11.2 may contribute to the susceptibility to neuropsychiatric or neurodevelopmental
problems. Von der Lippe et al. [139] and Stefansson et al. [140] found that the 15q11.2
deletion affects brain structures with similar alterations to the ones observed during the
first-episode psychosis in schizophrenia. The microdeletions and microduplications of
chromosome 16p11.2 region confer susceptibility to certain psychiatric disorders such as
schizophrenia and autism spectrum disorder [20,141,142].
In addition to common variants with a weak effect, pharmacogenomic data have
revealed rare variants (0.1 to 1%), taking the form of CNVs or SNPs, as potential candidate
loci [120]. This is most often de novo mutation, responsible for a loss of function (LoF).
Thus, 40 rare variants identified in the exon region coding for the NMDA receptor and
in the DRIN2C or GRIN2D genes are LoF mutations. The rare or de novo CNVs appear
in populations of patients with schizophrenia at a frequency twice as high as the control
individuals (5.1% vs. 2.2% in controls) [143]. Of these CNVs, 4 loci were known to be
associated with schizophrenia (3q29, 15q11.2, 15q13.3, and 16p11.2). Some rare CNVs are
enriched in genes encoding glutamatergic proteins [144], supporting the hypothesis that
rare variants responsible for loss of function in the glutamatergic pathway are important
for synaptic plasticity and cognition, playing a significant role in the pathogenesis of
schizophrenia [120,144].
Recently, a study combining GWAS data and data from a meta-analysis in 11,260 cases
of schizophrenia and 24,542 control cases identified 50 new loci and 33 candidate genes for
schizophrenia. The authors show also that genes subjected to high selective pressures are
strongly enriched with common variants (SNPs), suggesting mutant-intolerant genes [145].
Mutant-intolerant genes are enriched with common variants at risk for neurodevelopmental
neurological disorders such as autism spectrum disorder or intellectual disability, or other
pathologies such as epilepsy, congenital heart disease, microcephaly, and obesity [120,146].
These genes account for a 30% proportion of heritability based on SNPs in schizophrenia. In
addition, this study revealed five sets of independent genes associated with schizophrenia,
including two sets found also in the CNV analysis, encoding proteins of the voltage-gated
calcium channel and 5-HT2C receptor complexes. These results confirm studies on rare
and common variants involving calcium channel genes in schizophrenia [145]. There is a
convergence of data between genes containing rare variants of schizophrenia and those
of GWAS in favor of two major functions: glutamatergic synaptic neurotransmission and
calcium channels.
Several SNPs and CNVs located in genes associated with glutathione metabolism have
been associated with schizophrenia. Glutathione plays an important role in brain protection
against oxidative stress as an intracellular antioxidant or regulator of the redox system.
Oxidative stress induced by a redox imbalance may particularly play a role in schizophrenia.
Neurons are vulnerable to damage by oxidative stress and the presence of oxidative stress is
found in many tissues of patients with schizophrenia. Glutathione can bind to the redox site
on the NMDA glutamatergic receptor. A rise of extracellular glutathione levels increased
glutamate-induced neuronal depolarization via NMDA receptor activation. Studies of
genetically modified mouse models with low glutathione levels show many similarities to
schizophrenia, including NMDA receptor hypofunction, alteration of inhibitory neurons to
parvalbumin and impaired cognitive behavior. In addition, these mice have myelinization
defects of many cortical bundles, as observed in patients, suggesting impaired connections
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by redox deregulation during development. Glutathione levels appear to be lower in
individuals with schizophrenia in the medial prefrontal cortex and higher in the medial
temporal lobe than in healthy controls [147].
Tables 3 and 4 summarize findings related to genomics and schizophrenia. Interest-
ingly, many CNVs (deletion/duplication) associated with schizophrenia are observed in
autism spectrum disorder but also in intellectual disability, developmental delay, epilepsy,
learning disorder, bipolar disorder, and many other neurodevelopmental disorders (see
Table 4), suggesting the existence of common genetic vulnerability shared by these dis-
orders. However, when Kirov et al. [133] scanned the genome for CNVs involved in
schizophrenia, but also in autism spectrum disorder, developmental delay, and intellec-
tual disability, they compared the risk for carriers of these variants to develop one or
more of these disorders, i.e., their genetic penetrance, and showed that penetrance for
schizophrenia was several times lower than for the other disorders. In any cases, the
fact that many CNVs (deletion/duplication) found in schizophrenia are also observed in
other psychiatric/mental disorders, strengthen the need to develop a dimensional and
transnosographic approach in research on schizophrenia.
Table 3. Candidate genes and loci associated with schizophrenia in cytogenetic, linkage, and genome wide
association studies.
Genomic Region
and Candidate Loci Gene Protein
Vulnerability genes for schizophrenia based on cytogenetic studies
t (1 ; 11) (q42.1; q14.3) DISC1 Disrupted in schizophrenia 1 or DISC1
22q11.21 Deletion COMT Catechol O-methyltransferase
Candidate genes for schizophrenia supported by linkage findings
1q23.3 NOS1APRGS4
Carboxyl-terminal PDZ-bonding domain of neuronal nitric oxide
synthase 1 adaptor protein
Regulator of G-protein signaling 4
6p22.3 DTNBP1 Dystrobrev in binding protein 1
8p12 NRG1 Neuregulin 1
13q33.2; 13q34 DAOA D-amino acid oxidase activator
Single Nucleotide Polymorphism (SNP) supported by genome wide association studies (GWAS)
11q23.2 DRD2 Dopamine receptor D2
7q21.11-q21.12 GRM3 Glutamate metabotropic receptor 3
16p13.2 GRIN2A Glutamate ionotropic receptor NMDA type subunit 2A
17p13.3 SRR Serine Racemase
5q33.2 GRIA1 Glutamate ionotropic receptor AMPA type subunit 1
12p13.33 CACNA1C Calcium voltage-gated channel subunit alpha 1 C
10p12.33-p12.31 CACNB2 Calcium voltage-gated channel auxiliary subunit beta 2
22q13.1 CACNA1l Calcium voltage-gated channel subunit alpha 1 l
Table 4. Copy number variants (CNV) associated with schizophrenia (SCZ) and other disorders.
Region and CNV Type (Microarray) Candidate Genes in the Region Phenotypes *
1q21.1 Deletion/Duplication HYDIN SCZ, ASD, ID, DD, ADHD, Anxiety,LD, IGE deficit
2p16.3 Deletion/Duplication NRXN1 SCZ, ASD, ID, TS
3q29 Deletion/Duplication PAK2, DLG1, PAK3, DLG3 SCZ, ASD, ID, ADHD, EP
7q11.23 Duplication
(Williams–Beuren syndrome region) SCZ, ASD, ID, EP
7q35-q36 Deletion EN2, CNTNAP2 SCZ, ASD, ID, EP
15q11.2 Deletion (Angelman syndrome/
Prader-Willi syndrome region) CYF1P1, TUBGCP5, NIPA1, NIPA2
SCZ, ASD, ID, DD, OCD,
IGE deficit
15q11-13 Duplication GABRA5, GABRB3, GABG3, UBE3A,SNRPN, CHRNA7 SCZ, ASD, ID, EP, Ataxia
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Table 4. Cont.
Region and CNV Type (Microarray) Candidate Genes in the Region Phenotypes *
15q13.3 Deletion/Duplication CHRNA7, OTUD7A SCZ, ASD, ID, DD, ADHD,LD, EP
16p11.2 Deletion/Duplication DOC2A, ERK1 SCZ, ID, DD, BD, EP, LD
16p13.11 Deletion/Duplication NDE1 SCZ, ASD, ID, ADHD, EP,IGE deficit
17q12 Deletion/Duplication Undefined SCZ, ASD, ID, EP
22q11.2 Deletion/Duplication
(DiGeorge/Vélocardio-facial syndrome region)
PRODH, COMT, DGCR6, TBX1,
CRKL, FGF8 ASD, SCZ, ID, DD, ADHD, EP, LD
22q13.3 Deletion SHANK3 SCZ, ASD, ID, DD
Xp22.31 Deletion/Duplication NLGN4 SCZ, ASD, ID, BD, TS
Xq13.1 Deletion/Duplication NLGN3 SCZ, ASD, ID, BD
Adapted from Tordjman et al. [20], Vassos et al. [72], Lacy and King [148], Malhotra and Sebat [149]. * Note: SCZ, Schizophrenia; ASD,
Autism Spectrum Disorder; ID, Intellectual Disability; ADHD, Attention Deficit Hyperactivity Disorder, DD, Developmental Delay; BD,
Bipolar Disorder; TS, Tourette syndrome; OCD, Obsessive Compulsive Disorder; EP, Epilepsy; LD, Learning Disorder.
Furthermore, it is noteworthy that some CNVs implicated in schizophrenia contain no
protein-coding genes, such as moderate repeats of DNA sequence (ribosomal DNA: rDNA)
coding for ribosomal RNA, with only a fraction of them transcriptionally active [150].
rDNA copy number is elevated in the genomes of individuals with schizophrenia [151] and
could explain the negative comorbidity reported between schizophrenia and rheumatoid
arthritis [150,152,153]. Ribosomal repeats are hypothesized to play a role in the pathogene-
sis of schizophrenia and autism spectrum disorder (ASD). For example, a carrier of very
low copy number of ribosomal genes is expected to have a milder form of ASD than an
individual with the same epigenetic and genetic background, but with a higher ribosomal
gene dosage [154]. Another non-coding repeats observed in schizophrenia are copy number
variations of satellite III (1q12). Cell content of the Sat III repeat in leukocytes of patients
with schizophrenia is significantly reduced compared to healthy controls. It has been
suggested that the low amount of Sat III DNA is one of the possible causes of oxidative
stress in the body of patients with schizophrenia [155]. The involvement of non-canonical
regions of the genome may explain the genetic predisposition observed in schizophrenia as
shown by twin studies, and the absence of strongly associated causative genes in most cases.
Future studies are required to understand better the genetic contribution to schizophrenia
of repeats of no protein-coding genes.
Taken together, genetic studies in schizophrenia show that many genetic variants have
been identified, but none with high penetrance. The genetic contribution in schizophrenia
is complex, not responding to a monogenic or oligogenic model. It is therefore likely the
combination of multiple genetic variants at risk with a modest effect in an individual
that leads to genetic vulnerability beyond a certain threshold. In this case, we speak of
multifactorial and polygenic disease. The highly polygenic nature was demonstrated in
2009 by estimating a risk score involving thousands of common variants with very low
effects on schizophrenia [156,157]. A genetic predisposition with the existence of mutations
or genetic variants is not enough to develop the disease which will be expressed under the
influence of environmental factors. Environmental factors have effects on genetic factors
through epigenetic modifications which modulate the expression of certain genes (histone
modification, chromatin remodeling, and DNA methylation). Very early gene/environment
interactions involve some genes of neurodevelopment. Late gene/environment interactions
involve genes responsible for dysfunction of the dopaminergic/glutamatergic system or
synaptic plasticity. These genetic abnormalities could increase neuronal vulnerability to
traumatic or toxic factors. Toxic factors such as regular cannabis intake, especially for
early onset consumption or high cumulative dose of THC (tetrahydrocannabinol), could
interact with genetic vulnerability factors to contribute to the development of psychosis.
Childhood and adolescence are critical periods of vulnerability to environmental impacts,
evoking the importance of physical and psychological trauma in the history of psychotic
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patients. Several models of stress vulnerability in schizophrenia have been proposed and
abnormal stress responses of the hypothalamic–pituitary–adrenal axis have been reported
in schizophrenia, as in autism spectrum disorder which shares certain common genetic
and physiological pathways with schizophrenia, especially with EOS [20,158,159]. Animal
models are of great interest to study Gene X Environment interactions in schizophrenia even
if these animal models offer more a dimensional approach rather than providing specific
categorical models of schizophrenia [160,161]. The Gene X Environment interaction model
shows that additional stress in young animals leads to a permanent deficit in parvalbumin
neurons and their perineuronal protection against oxidative stress, whereas it remains
without ant effects in adult animals [162]. Furthermore, Janssen et al. [163] established a
strong dose–response relationship between childhood abuse and psychosis after tracking
4045 people in the general population for two years. These data support a significant role
of genetic factors and the implication of environmental stressful events in the development
of the disease, suggesting that schizophrenia is a neurodevelopmental disorder.
Given the complexity of the genetics of schizophrenia, genomic data are insufficient
to obtain a functional vision of the system; it becomes essential to be able to combine these
data with those obtained by functional genomic techniques which explore the expression
of genes in level of transcriptome, proteome, and metabolome. These data will open
a new field of understanding of the various molecular mechanisms that influence the
development of schizophrenia and the various symptomatology that result from it. The
candidate genes approach is still relevant to understand these molecular mechanisms. It
makes it possible to analyze the various potential targets with a more integrative and
global approach using specific animal or cellular models for these susceptibility genes.
In line with this strategy, genetically modified mice have been developed to determine
better the role of different NMDA receptors in cognitive functions. These studies made it
possible to explore individually the influence of the different specific subtypes of NMDA
receptors [111].
5. Minor Physical Anomalies
In 1985, Kraepelin reported morphological abnormalities in patients with dementia
praecox [164]. More recent studies agree that some morphological abnormalities are more
common in individuals with schizophrenia compared to the general population—including
palatal arches, epicanthus and telecanthus, bradycephaly, and prominent ears [165]. The
prevalence of minor physical abnormalities could reach 62.7% according to some studies in
patients with first-episode psychosis but with a great variety in the observed abnormali-
ties [166]. The variety of minor morphological abnormalities is described in a meta-analysis
of 13 studies [167]. These abnormalities are not specific to schizophrenia but could help
in identifying earlier this psychiatric disorder, especially if they are associated with ge-
netic and/or environmental risk factors for schizophrenia (including family history of
schizophrenia). However, three signs appear to be robust: facial asymmetry, anomaly of the
palatal vault, and atypical capillary implantation [167]. A prospective study [168] showed
that the number of minor morphological abnormalities measured in children between 11
and 13 years was a risk factor for the onset of schizophrenia in adulthood (RR = 3.5). These
anomalies were also associated with age at onset of schizophrenia and not with clinical
severity; more precisely, minor physical anomalies were more frequent in patients with
early onset schizophrenia (i.e., with onset before age 18 years) compared to later onset
patients [169]. Missaoui et al. [170] confirm these previous studies. They reported that EOS
patients, besides showing a greater severity of schizophrenia and negative symptomatology
compared to individuals with later onset schizophrenia, had also more frequently minor
physical and neurological abnormalities, including abnormalities of the face, hands, and
ears. Gourion et al. [164] showed also that patients with schizophrenia and their parents
have minor morphological abnormalities more frequently than non-affected individuals.
The interest of these results is to highlight the possible role of genetic and/or environ-
mental prenatal risk factors for schizophrenia (such as maternal infections or maternal
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bleeding, exposure to toxins, fetal anoxia [171]). Minor physical abnormalities would be the
clinical expression of disturbances in the early development of the central nervous system
(including the development of the ectoderm and neural ridges) and would therefore be in
favor of the neurodevelopmental hypothesis [168].
Already, in 1997, Lewis reported a global reduction from 5% to 8% of cortical grey
matter in patients with schizophrenia, not correlated with the duration of schizophrenia,
suggesting the existence of an early neurodevelopmental process rather than a degenerative
one [172]. More recently, Shenton and Kubicki [173] concluded that neuroimaging abnor-
malities found in individuals with schizophrenia are in favor of connectivity problems
between brain areas, probably stemming from neurodevelopmental impairments. Several
brain morphological changes have been described in schizophrenia based on neuroimaging
which can reflect the impact of genetic but also environmental factors on brain structure
and function [174,175]. More precisely, decreased cerebral volume (post-mortem examina-
tions and in vivo neuroimaging) have been reported in schizophrenia. Volume changes
mainly affect the frontal, prefrontal, and temporal regions, as well as limbic structures.
Imbalance between grey and white matter, consisting of excessive grey matter loss and
reduced white matter integrity, was also reported (for a review, see Wilczynska et al. [174]).
Microscopic studies observed changes in neuronal density, myelin structure and astroglia
and oligodendroglia, as well as size and shape of dendritic spines within synaptic con-
nections. These findings are consistent with studies on activity of immunohistochemical
markers such as parvalbumin, microtubule associated proteins or receptor markers, as well
as neurofunctional imaging where impairments in blood flow, glucose metabolism and
phospholipid catabolism are found within the atrophic structures. Some of those changes
are related to clinical characteristics or factors such as severity of symptoms, type of ap-
plied treatment or neurological soft signs (these clinical signs were found to be associated
with cortical, thalamic, and cerebellar changes in schizophrenia [174,175]). These brain
morphological changes, taken together, support the neurodevelopmental hypothesis. In
this context, research on minor morphological abnormalities as developmental markers of
vulnerability highlights the importance of clinical genetic examination to detect dysmor-
phic features, rarely explored systematically in patients with psychiatric disorders but very
useful for identifying genetic disorders associated with schizophrenia (see Table 2) and
guiding diagnostic strategy (neuroimaging, oriented by the clinical results from clinical
genetic and neurological examinations, can be requested if necessary).
6. Conclusions: Importance of a Clinical Genetic Examination in Schizophrenia
In the light of our observations, a clinical genetic examination appears to be an essential
prerequisite for UHR individuals, as it allows an extended physical examination of the
whole body to detect morphological abnormalities, including minor physical anomalies. It
could be conducted on any patients showing prodroma signs of schizophrenia, searching
for neurodevelopmental abnormalities in favor, as seen in this article, of vulnerability
factors to schizophrenia. This examination should be performed by a trained clinical
geneticist to detect dysmorphic features or malformations. It includes photos of the head
(face and profile) with a good visibility of eyes and ears, as well as hands (palm and dorsal
view) and feet. In the absence of easily access to clinical geneticists, the alternative option
of using Face2gene software (developed by FDNA: Facial Dysmorphology Novel Analysis)
is possible as a first step of exploration before a clinical genetic examination [176]. This
software is a fast and accessible tool allowing the detection of dysmorphic signs based on
the computer analyses of facial pictures with a reliable reproducibility. Its use in current
practice allows an exploration of morphological abnormalities with clinical acceptability,
high feasibility, and privileged access to the developmental history of patients. Finally,
a physical examination of clinical genetics has an important role in the strategy of early
identification of individuals with schizophrenia and genetic disorders associated with
schizophrenia. Clinical genetic evaluation can greatly benefit from examining children and
adolescents repeatedly over time to follow their developmental trajectory, including the
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evolution of morphological anomalies, and from examining at the same time the patient,
his or her parents and siblings to compare the findings. The identification of genetic
disorders associated with schizophrenia based on clinical genetic examination, has practical
implications for diagnostic strategies, early detection or prevention of co-morbidity, specific
treatment, follow up, and genetic counseling.
Author Contributions: A.-C.P., L.D., G.B., M.T. and S.T. wrote the first draft of the manuscript. All
these authors and M.-M.G. participated to the revision of the manuscript. All authors have read and
agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing:
Arlington, VA, USA, 2013.
2. World Health Organization. ICD-10: The ICD-10 Classification of Mental and Behavioural disorders: Clinical Descriptions and Diagnostic
Guidelines; World Health Organisation: Geneva, Switzerland, 1992.
3. Remschmidt, H.E.; Theisen, F. Early-onset schizophrenia. Neuropsychobiology 2012, 66, 63–69. [CrossRef]
4. McClellan, J.; Stock, S. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Schizophrenia. J.
Am. Acad. Child Adolesc. Psychiatry 2013, 52, 976–990. [CrossRef]
5. Meyer-Lindenberg, A. From maps to mechanisms through neuroimaging of schizophrenia. Nat. Cell Biol. 2010, 468, 194–202.
[CrossRef] [PubMed]
6. Lewine, R.R.J.; Watt, N.F.; Prentky, R.A.; Fryer, J.H. Childhood Behaviour in Schizophrenia, Personality Disorder, Depression, and
Neurosis. Br. J. Psychiatry 1978, 133, 347–357. [CrossRef]
7. Larsen, T.K.; McGlashan, T.H.; Moe, L.C. First-episode Schizophrenia: I. Early Course Parameters. Schizophr. Bull. 1996, 22,
241–256. [CrossRef]
8. Ingraham, L.J.; Kugelmass, S.; Frenkel, E.; Nathan, M.; Mirsky, A.F. Twenty-five-year Followup of the Israeli High-risk Study:
Current and Lifetime Psychopathology. Schizophr. Bull. 1995, 21, 183–192. [CrossRef] [PubMed]
9. Keshavan, M.S.; Diwadkar, V.A.; Montrose, D.M.; Rajarethinam, R.; Sweeney, J.A. Premorbid indicators and risk for schizophrenia:
A selective review and update. Schizophr. Res. 2005, 79, 45–57. [CrossRef]
10. Nicolson, R.; Rapoport, J.L. Childhood-onset schizophrenia: Rare but worth studying. Biol. Psychiatry 1999, 46, 1418–1428.
[CrossRef]
11. Krebs, M.O. Early detection and intervention: A change in paradigm. Ann. Med. Psy. 2018, 176, 65–69.
12. Chapman, J. The Early Symptoms of Schizophrenia. Br. J. Psychiatry 1966, 112, 225–251. [CrossRef]
13. Zaytseva, Y.; Korsakova, N.; Agius, M.; Gurovich, I. Neurocognitive Functioning in Schizophrenia and during the Early Phases of
Psychosis: Targeting Cognitive Remediation Interventions. BioMed Res. Int. 2013, 2013, 1–8. [CrossRef] [PubMed]
14. McGlashan, T.H. Early detection and intervention of schizophrenia: Rationale and research. Br. J. Psychiatry 1998, 172, 3–6.
[CrossRef]
15. Conus, P.; Polari, A.; Bonsack, C. Intervention dans la phase précoce des troubles psychotiques: Objectifs et organisation du
programme TIPP (Traitement et intervention dans la phase précoce des troubles psychotiques) à Lausanne. L’information Psychiatr.
2010, 86, 145. [CrossRef]
16. Debnath, M.; Venkatasubramanian, G.; Berk, M. Fetal programming of schizophrenia: Select mechanisms. Neurosci. Biobehav. Rev.
2015, 49, 90–104. [CrossRef] [PubMed]
17. Millan, M.J.; Andrieux, A.; Bartzokis, G.; Cadenhead, K.; Dazzan, P.; Fusar-Poli, P.; Gallinat, J.; Giedd, J.; Grayson, D.R.; Heinrichs,
M.; et al. Altering the course of schizophrenia: Progress and perspectives. Nat. Rev. Drug Discov. 2016, 15, 485–515. [CrossRef]
18. Keshavan, M.S. Development, disease and degeneration in schizophrenia: A unitary pathophysiological model. J. Psychiatr. Res.
1999, 33, 513–521. [CrossRef]
19. Douaud, G.; Mackay, C.; Andersson, J.; James, S.; Quested, D.; Ray, M.K.; Connell, J.; Roberts, N.; Crow, T.J.; Matthews, P.M.; et al.
Schizophrenia delays and alters maturation of the brain in adolescence. Brain 2009, 132, 2437–2448. [CrossRef]
20. Tordjman, S.; Cohen, D.; Anderson, G.; Botbol, M.; Canitano, R.; Coulon, N.; Roubertoux, P. Repint of “Reframing autism as
a behavioral syndrome and not a specific mental disorder: Implications of genetic and phenotypic heterogeneity”. Neurosci.
Biobehav. Rev. 2018, 89, 132–150. [CrossRef]
21. Hossein, F.S.; Folsom, T.D. The Neurodevelopmental Hypothesis of Schizophrenia. Schizophr. Bull. 2009, 35, 528–548.
22. Bayer, T.A.; Falkai, P.; Maier, W. Genetic and non-genetic vulnerability factors in schizophrenia: The basis of the “two hit
hypotheses”. J. Psychiatr. Res. 1999, 33, 543–548. [CrossRef]
23. Morrison, A.P.; French, P.; Walford, L.; Lewis, S.W.; Kilcommons, A.; Green, J.; Green, J.; Parker, S.; Bentall, R.P. Cognitive therapy
for the prevention of psychosis in people at ultra-high risk: Randomized controlled trial. Br. J. Psychiatry 2004, 185, 291–297.
[CrossRef]
Int. J. Mol. Sci. 2021, 22, 9464 17 of 22
24. Bombin, I.; Arango, C.; Buchanan, R.W. Significance and Meaning of Neurological Signs in Schizophrenia: Two Decades Later.
Schizophr. Bull. 2005, 31, 962–977. [CrossRef]
25. Krebs, M.-O.; Mouchet, S. Signes neurologiques mineurs et schizophrénie: Revue des données actuelles. Rev. Neurol. 2007, 163,
1157–1168. [CrossRef]
26. Fountoulakis, K.N.; Panagiotidis, P.; Kimiskidis, V.; Nimatoudis, I.; Gonda, X. Neurological soft signs in familial and sporadic
schizophrenia. Psychiatry Res. 2018, 272, 222–229. [CrossRef]
27. Chan, R.C.; Gottesman, I. Neurological soft signs as candidate endophenotypes for schizophrenia: A shooting star or a Northern
star? Neurosci. Biobehav. Rev. 2008, 32, 957–971. [CrossRef]
28. Gaha, S.B.; Dhouib, S.H.; Amado, I.; Bouden, A. Signes neurologiques mineurs dans la schizophrénie précoce. L’Encéphale 2015,
41, 209–214. [CrossRef]
29. Chan, R.C.K.; Xu, T.; Heinrichs, R.W.; Yu, Y.; Wang, Y. Neurological Soft Signs in Schizophrenia: A Meta-analysis. Schizophr. Bull.
2009, 36, 1089–1104. [CrossRef] [PubMed]
30. Biswas, P.; Malhotra, S.; Gupta, N. Comparative study of neurological soft signs in schizophrenia with onset in childhood,
adolescence and adulthood. Acta Psychiatr. Scand. 2007, 115, 295–303. [CrossRef] [PubMed]
31. Lee Gregory, M.; Burton, V.J.; Shapiro, B.K. Chapter 3—Developmental Disabilities and Metabolic Disorders. Neurobiology of Brain
Disorders; Academic Press: San Diego, CA, USA, 2015; pp. 18–41.
32. Gottesman, I.I.; Gould, T.D. The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions. Am. J. Psychiatry
2003, 160, 636–645. [CrossRef]
33. Glahn, D.C.; Knowles, E.E.; McKay, D.R.; Sprooten, E.; Raventos, H.; Blangero, J.; Gottesman, I.; Almasy, L. Arguments for the
sake of endophenotypes: Examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am. J.
Med Genet. Part B Neuropsychiatr. Genet. 2014, 165, 122–130. [CrossRef] [PubMed]
34. Hilker, R.; Helenius, D.; Fagerlund, B.; Skytthe, A.; Christensen, K.; Werge, T.M.; Nordentoft, M.; Glenthøj, B. Heritability of
Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. Biol. Psychiatry 2018, 83, 492–498.
[CrossRef] [PubMed]
35. Cardno, A.G.; Marshall, E.J.; Coid, B.; Macdonald, A.M.; Ribchester, T.R.; Davies, N.J.; Venturi, P.; Jones, L.A.; Lewis, S.W.; Sham,
P.C.; et al. Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series. Arch. Gen. Psychiatry 1999, 56,
162–168. [CrossRef] [PubMed]
36. Kébir, O.; Tarabeux, J.; Krebs, M.-O. Pathologies Schizophréniques; Facteurs Génétiques dans la Schizophrénie; Jean, D., Ed.;
Lavoisier: France, Paris, 2012; pp. 213–226.
37. Gottesman, I.; Shields, J.; Hanson, D.R. Schizophrenia: The Epigenetic Puzzle; Cambridge University Press: Cambridge, UK, 1982.
38. Larson, C.A.; Nyman, G.E. Differential fertility in schizophrenia. Acta Psychiatr. Scand. 1973, 49, 272–280. [CrossRef] [PubMed]
39. Gottesman, I.; Shields, J. Schizophrenia and genetics: A twin study vantage point. Am. J. Hum. Genet. 1976, 28, 630–631.
40. Maier, W.; Lichtermann, D.; Franke, P.; Heun, R.; Falkai, P.; Rietschel, M. The dichotomy of schizophrenia and affective disorders
in extended pedigrees. Schizophr. Res. 2002, 57, 259–266. [CrossRef]
41. Thibaut, F. Génétique de la Schizophrénie; John Libbey Eurotext: Montrouge, France, 2003.
42. Charrier, A.; Olliac, B.; Roubertoux, P.; Tordjman, S. Clock genes and altered sleep-wake rhythms: Their role in the development
of psychiatrc disorders. Int. J. Mol. Sci. 2017, 18, 938. [CrossRef]
43. Gorwood, P.; Leboyer, M.; Jay, M.; Payan, C.; Feingold, J. Gender and age at onset in schizophrenia: Impact of family history. Am.
J. Psychiatry 1995, 152, 208–212. [CrossRef]
44. Svensson, A.C.; Lichtenstein, P.; Sandin, S.; Öberg, S.; Sullivan, P.F.; Hultman, C.M. Familial aggregation of schizophrenia: The
moderating effect of age at onset, parental immigration, paternal age and season of birth. Scand. J. Public Heal. 2011, 40, 43–50.
[CrossRef]
45. Kallmann, F.J.; Roth, B. Genetic aspects of preadolescent schizophrenia. Am. J. Psychiatry 1956, 112, 599–606. [CrossRef]
46. Cardno, A.G.; Gottesman, I.I. Twin studies of schizophrenia: From bow-and-arrow concordances to star-wars Mx and functional
genomics. Am. J. Med. Genet. 2000, 97, 12–17. [CrossRef]
47. Sullivan, P.F.; Kendler, K.S.; Neale, M.C. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch.
Gen. Psychiatry 2003, 60, 1187–1192. [CrossRef]
48. Luxenberger, H. Vorläufiger Bericht über psychiatrisch Serienun terschungen an Zwillingen. Zeitschrift Gesamte Neurol. Psychiatr.
1928, 116, 297–326. [CrossRef]
49. Rosanoff, A.J.; Hand, L.M.; Pleset, I.R.; Brush, S. The etiology of so-called schizophrenic psychoses. Am. J. Psychiatry 1934, 91,
247–286. [CrossRef]
50. Kallmann, F.J. Heredity in Health and Mental Disorder; Norton & Company: New York, NY, USA, 1953; Volume 3, p. 251.
51. Slater, E.; Shields, J. Psychotic and Neurotic Illness in Twins. Med. Res. Council Special Rep. Ser. 1953, 278, 1–385.
52. Inouye, E. Similarity and Dissimilarity of Schizophrenia in Twins: In Proceedings of the Third World Congress of Psychiatry.
University of Toronto Press: Montreal, Toronto, ON, Canada, 1961; Volume 1, pp. 530–542.
53. Tienari, P. Psychiatric illnesses in identical twins. Acta Psychiatr. Scand. 1963, 39, 1–195.
54. Kringlen, E. Heredity and Environment in the Functional Psychoses; Elsevier: Amsterdam, The Netherlands, 1967; p. 202.
55. Fischer, M.; Harvald, B.; Hauge, M. A Danish Twin Study of Schizophrenia. Br. J. Psychiatry 1969, 115, 981–990. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 9464 18 of 22
56. Essen-Möller, E. Twenty-one Psychiatric Cases and their MZ Cotwins A thirty years’ follow-up. Acta Genet. Med. Gemellol. 1970,
19, 315–317. [CrossRef] [PubMed]
57. Fischer, M. Genetic and environmental factors in schizophrenia. A study of schizophrenic twins and their families. Acta Psychiatr.
Scand. Suppl. 1973, 238, 9–142. [PubMed]
58. Kendler, K.S.; Robinette, C.D. Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: A
16-year update. Am. J. Psychiatry 1983, 140, 1551–1563. [CrossRef] [PubMed]
59. Onstad, S.; Skre, I.; Torgersen, S.; Kringlen, E. Twin concordance for DSM-III-R schizophrenia. Acta Psychiatr. Scand. 1991, 83,
395–401. [CrossRef] [PubMed]
60. Franzek, E.; Beckmann, H. Different genetic background of schizophrenia spectrum psychosis: A twin study. Am. J. Psychiatry
1998, 155, 76–83. [CrossRef] [PubMed]
61. Kringlen, E.; Cramer, G. Offspring of Monozygotic Twins Discordant for Schizophrenia. Arch. Gen. Psychiatry 1989, 46, 873.
[CrossRef]
62. Gottesman, I.I.; Bertelsen, A. Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer’s Danish
identical and fraternal discordant twins. Arch. Gen. Psychiatry 1989, 46, 867–872. [CrossRef]
63. Jones, B.C.; Mormede, P. Neurobehavioral Genetics: Methods and Applications; CRC Press: Boca Raton, FL, USA, 2002.
64. Slater, E.; Cowie, V. The Genetics of Mental Disorder. J. Neurol. Sci. 1972, 17, 365.
65. Kety, S.S.; Rosenthal, D.; Wender, P.H.; Schulsinger, F.; Jacobsen, B. Mental illness in the biological and adoptive families of
adopted individuals who have become schizophrenic: A preliminary report based on psychiatric interviews. Proc. Annu. Meet.
Am. Psychopathol. Assoc. 1975, 63, 147–165. [CrossRef]
66. Lichtenstein, P.; Yip, B.H.K.; Björk, C.; Pawitan, Y.; Cannon, T.D.; Sullivan, P.F.; Hultman, C.M. Common genetic determinants of
schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009, 373, 234–239. [CrossRef]
67. Higgins, J. Effects of child rearing by schizophrenic mothers: A follow-up. J. Psychiatr. Res. 1976, 13, 1–9. [CrossRef]
68. Maubert, A.; Hanon, C.; Metton, J.P. Adult onset Niemann-Pick type C disease and psychosis: Litterature review. Encephale 2013,
39, 315–319. [CrossRef]
69. Eljebbouri, F.F.; Laboudi, A. Ouanass, Intermittent acute porphyry and schizophrenia: About a case. Int. J. Adv. Res. 2018, 6,
1231–1233. [CrossRef]
70. Walterfang, M.; Fietz, M.; Fahey, M.; Sullivan, D.; Leane, P.; Lubman, D.I.; Velakoulis, D. The Neuropsychiatry of Niemann-Pick
Type C Disease in Adulthood. J. Neuropsychiatry Clin. Neurosci. 2006, 18, 158–170. [CrossRef]
71. Kobrynski, L.J.; Sullivan, K. Velocardiofacial syndrome, DiGeorge syndrome: The chromosome 22q11.2 deletion syndromes.
Lancet 2007, 370, 1443–1452. [CrossRef]
72. Vassos, E.; Collier, D.A.; Holden, S.; Patch, C.; Rujescu, D.; Clair, D.S.; Lewis, C.M. Penetrance for copy number variants associated
with schizophrenia. Hum. Mol. Genet. 2010, 19, 3477–3481. [CrossRef]
73. Messias, E.; Kaley, S.N.; McKelvey, K.D. Adult-Onset Psychosis and Clinical Genetics: A Case of Phelan-McDermid Syndrome. J.
Neuropsychiatry Clin. Neurosci. 2013, 25, 27. [CrossRef]
74. Gauthier, J.; Champagne, N.; Lafrenière, R.G.; Xiong, L.; Spiegelman, D.; Brustein, E.; Lapointe, M.; Peng, H.; Côté, M.; Noreau, A.;
et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.
Proc. Natl. Acad. Sci. USA 2010, 107, 7863–7868. [CrossRef]
75. Van Buggenhout, G.; Fryns, J.-P. Lujan-Fryns syndrome (mental retardation, X-linked, marfanoid habitus). Orphanet J. Rare Dis.
2006, 1, 26. [CrossRef]
76. Hert, M.; Steemans, D.; Theys, P.; Fryns, J.P.; Peuskens, J. Lujan-Fryns syndrome in the differential diagnosis of schizophrenia.
Am. J. Med. Genet. 1996, 67, 212–214. [CrossRef]
77. Lemberg, M.; Thompson, A.W. Marfan syndrome and schizophrenia: A case report and literature review. Gen. Hosp. Psychiatry
2010, 32, 228.e9–228.e10. [CrossRef]
78. Mercuro, G.; Ruscazio, M.; Zoncu, S.; Montisci, R.; Cherchi, A.; Carpiniello, B.; Rudas, N. Association between psychiatric
disorders and marfan’s syndrome in a large sardinian family with a high prevalence of cardiac abnormalities. Clin. Cardiol. 1997,
20, 243–245. [CrossRef] [PubMed]
79. Chamberlain, S.J.; Chen, P.-F.; Ng, K.Y.; Bourgois-Rocha, F.; Lemtiri-Chlieh, F.; Levine, E.; Lalande, M. Induced pluripotent stem
cell models of the genomic imprinting disorders Angelman and Prader–Willi syndromes. Proc. Natl. Acad. Sci. USA 2010, 107,
17668–17673. [CrossRef] [PubMed]
80. Mabb, A.; Judson, M.C.; Zylka, M.J.; Philpot, B.D. Angelman syndrome: Insights into genomic imprinting and neurodevelopmen-
tal phenotypes. Trends Neurosci. 2011, 34, 293–303. [CrossRef] [PubMed]
81. Cassidy, S.B.; Schwartz, S.; Miller, J.L.; Driscoll, D.J. Prader-Willi syndrome. Genet. Med. 2011, 14, 10–26. [CrossRef]
82. Somerville, M.J.; Mervis, C.B.; Young, E.J.; Seo, E.-J.; Del Campo, M.; Bamforth, S.; Peregrine, E.; Loo, W.; Lilley, M.; Pérez-Jurado,
L.A.; et al. Severe Expressive-Language Delay Related to Duplication of the Williams–Beuren Locus. N. Engl. J. Med. 2005, 353,
1694–1701. [CrossRef]
83. Van der Aa, N.; Rooms, L.; Vandeweyer, G.; Ende, J.V.D.; Reyniers, E.; Fichera, M.; Romano, C.; Chiaie, B.D.; Mortier, G.; Menten,
B.; et al. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. Eur. J. Med Genet. 2009,
52, 94–100. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 9464 19 of 22
84. Mulle, J.G.; Pulver, A.E.; McGrath, J.A.; Wolyniec, P.S.; Dodd, A.F.; Cutler, D.J.; Sebat, J.; Malhotra, D.; Nestadt, G.; Conrad,
D.F.; et al. Reciprocal Duplication of the Williams-Beuren Syndrome Deletion on Chromosome 7q11.23 Is Associated with
Schizophrenia. Biol. Psychiatry 2014, 75, 371–377. [CrossRef]
85. Kirov, G.; Rees, E.; Walters, J.; Escott-Price, V.; Georgieva, L.; Richards, A.L.; Chambert, K.D.; Davies, G.; Legge, S.; Moran, J.;
et al. The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay. Biol. Psychiatry 2014, 75, 378–385.
[CrossRef]
86. Cerone, R.; Schiaffino, M.C.; Caruso, U.; Lupino, S.; Gatti, R. Minor facial anomalies in combined methylmalonic aciduria and
homocystinuria due to a defect in cobalamin metabolism. J. Inherit. Metab. Dis. 1999, 22, 247–250. [CrossRef]
87. Almuqbil, M.A.; Waisbren, S.E.; Levy, H.L.; Picker, J.D. Revising the Psychiatric Phenotype of Homocystinuria. Genet. Med. 2019,
21, 1827–1831. [CrossRef] [PubMed]
88. Black, D.N.; Taber, K.; Robin, A.; Hurley, R.A. Metachromatic leukodystrophy: A model for the study of psychosis. J. Neuropsychi-
atry Clin. Neurosci. 2003, 15, 289–293. [CrossRef] [PubMed]
89. Zimbrean, P.C.; Schilsky, M.L. Psychiatric aspects of Wilson disease: A review. Gen. Hosp. Psychiatry 2014, 36, 53–62. [CrossRef]
90. Numata, S.; Ueno, S.-I.; Iga, J.-I.; Song, H.; Nakataki, M.; Tayoshi, S.; Sumitani, S.; Tomotake, M.; Itakura, M.; Sano, A.; et al.
Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population. J. Psychiatr. Res.
2008, 43, 7–12. [CrossRef] [PubMed]
91. Hodgkinson, C.A.; Goldman, D.; Jaeger, J.; Persaud, S.; Kane, J.M.; Lipsky, R.H.; Malhotra, A.K. Disrupted in Schizophrenia 1
(DISC1): Association with Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder. Am. J. Hum. Genet. 2004, 75, 862–872.
[CrossRef]
92. Sinha, V.; Hennah, W.; Ukkola-Vuoti, L.; Ortega-Alonso, A.; Partonen, T.; Torniainen, M.; Hovatta, I.; Cannon, T.; Paunio, T.;
Haukka, J.; et al. THE DISC1 GENE AND MAJOR MENTAL ILLNESS IN FINLAND. Eur. Neuropsychopharmacol. 2019, 29,
S1010–S1011. [CrossRef]
93. Stone, J.L.; O’Donovan, M.C.; Gurling, H.; Kirov, G.K.; Blackwood, D.H.R.; Corvin, A.; Lichtenstein, P. Rare chromosomal
deletions and duplications increase risk of schizophrenia. Nature 2008, 455, 237–241.
94. Dolcetti, A.; Silversides, C.K.; Marshall, C.R.; Lionel, A.C.; Stavropoulos, D.J.; Scherer, S.W.; Bassett, A.S. 1q21.1 Microduplication
expression in adults. Genet. Med. 2012, 15, 282–289. [CrossRef]
95. Bernier, R.; Steinman, K.; Reilly, B.; Wallace, A.S.; Sherr, E.H.; Pojman, N.; Mefford, H.C.; Gerdts, J.; Earl, R.; Hanson, E.; et al.
Clinical phenotype of the recurrent 1q21.1 copy-number variant. Genet. Med. 2015, 18, 341–349. [CrossRef] [PubMed]
96. Stefansson, H.; Rujescu, D.; Cichon, S.; Pietiläinen, O.P.H.; Ingason, A.; Steinberg, S.; Fossdal, R.; Sigurdsson, E.; Sigmundsson, T.
Large recurrent microdeletions associated with schizophrenia. Nat. Cell Biol. 2008, 455, 232–236. [CrossRef]
97. The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nat.
Cell Biol. 2008, 455, 237–241. [CrossRef]
98. Sharp, A.J.; Mefford, H.C.; Li, K.; Baker, C.; Skinner, C.; Stevenson, R.; Schroer, R.J.; Novara, F.; De Gregori, M.; Ciccone, R.; et al.
A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat. Genet. 2008, 40, 322–328.
[CrossRef] [PubMed]
99. Milunsky, J.; Huang, X.-L.; Wyandt, H.; Milunsky, A. Schizophrenia susceptibility gene locus at Xp22.3. Clin. Genet. 1999, 55,
455–460. [CrossRef]
100. McCarthy Shane, E.; Makarov, V.; Sebat, J. Microduplications of 16p11.2 are associated with schizophrenia. Nat. Genet. 2009, 41,
1223–1227. [CrossRef]
101. Bonnot, O.; Tanguy, M.-L.; Consoli, A.; Cornic, F.; Graindorge, C.; Laurent, C.; Tordjman, S.; Cohen, D. Does catatonia influence
the phenomenology of childhood onset schizophrenia beyond motor symptoms? Psychiatry Res. 2008, 158, 356–362. [CrossRef]
102. Margari, L.; Margari, F.; Presicci, A.; Petruzzelli, M.G.; Ventura, P.; Dicuonzo, F.; Palma, M. Very early onset and greater
vulnerability in schizophrenia: A clinical and neuroimaging study. Neuropsychiatr. Dis. Treat. 2008, 4, 825–830. [CrossRef]
103. Driver, D.I.; Gogtay, N.; Rapoport, J.L. Childhood Onset Schizophrenia and Early Onset Schizophrenia Spectrum Disorders. Child
Adolesc. Psychiatr. Clin. North Am. 2013, 22, 539–555. [CrossRef]
104. Murphy, K.C.; Jones, L.A.; Owen, M.J. High Rates of Schizophrenia in Adults with Velo-Cardio-Facial Syndrome. Arch. Gen.
Psychiatry 1999, 56, 940–945. [CrossRef] [PubMed]
105. Tunbridge, E.; Harrison, P.J.; Weinberger, D.R. Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond.
Biol. Psychiatry 2006, 60, 141–151. [CrossRef]
106. Ross, C.A.; Margolis, R.L.; Reading, S.A.; Pletnikov, M.; Coyle, J.T. Neurobiology of Schizophrenia. Neuron 2006, 52, 139–153.
[CrossRef] [PubMed]
107. Schwartz, T.L.; Esachdeva, S.; Stahl, S.M. Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia. Front.
Pharmacol. 2012, 3, 195. [CrossRef] [PubMed]
108. Nucifora, F.C.; Woznica, E.; Lee, B.J.; Cascella, N.; Sawa, A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic
perspectives. Neurobiol. Dis. 2018, 131, 104257. [CrossRef] [PubMed]
109. Javitt, D.C.; Zukin, S. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148, 1301–1308.
[CrossRef]
Int. J. Mol. Sci. 2021, 22, 9464 20 of 22
110. Krystal, J.H.; Karper, L.P.; Seibyl, J.P.; Freeman, G.K.; Delaney, R.; Bremner, J.D.; Heninger, G.R.; Bowers, M.B.; Charney, D.S.
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans. Arch. Gen. Psychiatry 1994, 51, 199–214.
[CrossRef]
111. Dauvermann, M.R.; Lee, G.; Dawson, N. Glutamatergic regulation of cognition and functional brain connectivity: Insights from
pharmacological, genetic and translational schizophrenia research. Br. J. Pharmacol. 2017, 174, 3136–3160. [CrossRef] [PubMed]
112. Howes, O.; McCutcheon, R.; Stone, J. Glutamate and dopamine in schizophrenia: An update for the 21st century. J. Psychopharma-
col. 2015, 29, 97–115. [CrossRef] [PubMed]
113. Stansley, B.J.; Conn, P.J. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr. Opin.
Pharmacol. 2018, 38, 31–36. [CrossRef]
114. Balu, D.T. The NMDA receptor and schizophrenia: From pathophysiology to treatment. Adv. Pharmacol. 2016, 76, 351–382.
[PubMed]
115. Hahn, C.-G.; Wang, H.-Y.; Cho, D.-S.; Talbot, K.; Gur, R.; Berrettini, W.H.; Bakshi, K.; Kamins, J.; Borgmann-Winter, K.; Siegel, S.J.;
et al. Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nat. Med. 2006, 12,
824–828. [CrossRef]
116. Homayoun, H.; Moghaddam, B. NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons
and Pyramidal Neurons. J. Neurosci. 2007, 27, 11496–11500. [CrossRef]
117. Snyder, M.A.; Gao, W.J. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front. Cell.
Neurosci. 2013, 7, 31. [CrossRef]
118. Glen, W.B.; Horowitz, B.; Carlson, G.C.; Cannon, T.D.; Talbot, K.; Jentsch, J.D.; Lavin, A. Dysbindin-1 loss compromises
NMDAR-dependent synaptic plasticity and contextual fear conditioning. Hippocampus 2013, 24, 204–213. [CrossRef]
119. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated
genetic loci. Nature 2014, 511, 421–427. [CrossRef] [PubMed]
120. Uno, Y.; Coyle, J.T. Glutamate in schizophrenia. Psychiatry Clin. Neurosci. 2019, 73, 204–215. [CrossRef] [PubMed]
121. Miyamoto, Y.; Yamada, K.; Noda, Y.; Mori, H.; Mishina, M.; Nabeshima, T. Hyperfunction of dopaminergic and serotonergic
neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci. 2003, 21, 750–757. [CrossRef]
122. Coyle, J.T. Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis. Cell. Mol. Neurobiol. 2006, 26, 363–382. [CrossRef]
123. Morita, Y.; Ujike, H.; Tanaka, Y.; Otani, K.; Kishimoto, M.; Morio, A.; Kotaka, T.; Okahisa, Y.; Matsushita, M.; Morikawa, A.; et al.
A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia. Biol. Psychiatry 2007, 61, 1200–1203. [CrossRef]
[PubMed]
124. Benneyworth, M.A.; Li, Y.; Basu, A.C.; Bolshakov, V.Y.; Coyle, J.T. Cell Selective Conditional Null Mutations of Serine Racemase
Demonstrate a Predominate Localization in Cortical Glutamatergic Neurons. Cell. Mol. Neurobiol. 2012, 32, 613–624. [CrossRef]
[PubMed]
125. Plitman, E.; Nakajima, S.; de la Fuente-Sandoval, C.; Gerretsen, P.; Chakravarty, M.M.; Kobylianskii, J.; Chung, J.K.; Caravaggio,
F.; Iwata, Y.; Remington, G.; et al. Glutamate-mediated excitotoxicity in schizophrenia: A review. Eur. Neuropsychopharmacol. 2014,
24, 1591–1605. [CrossRef] [PubMed]
126. Balu, D.; Li, Y.; Puhl, M.D.; Benneyworth, M.A.; Basu, A.C.; Takagi, S.; Bolshakov, V.Y.; Coyle, J.T. Multiple risk pathways for
schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci.
USA 2013, 110, E2400–E2409. [CrossRef]
127. Sahoo, T.; Theisen, A.; Rosenfeld, J.A.; Lamb, A.N.; Ravnan, J.B.; Schultz, R.A.; Torchia, B.S.; Neill, N.J.; Casci, I.; Bejjani, B.A.; et al.
Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays
and behavior problems. Genet. Med. 2011, 13, 868–880. [CrossRef]
128. Marshall, C.R.; Psychosis Endophenotypes International Consortium; Howrigan, D.P.; Merico, D.; Thiruvahindrapuram, B.;
Wu, W.; Greer, D.S.; Antaki, D.; Shetty, A.; Holmans, P.; et al. Contribution of copy number variants to schizophrenia from a
genome-wide study of 41,321 subjects. Nat. Genet. 2016, 49, 27–35. [CrossRef]
129. Südhof, T.C. Neuroligins and neurexins link synaptic function to cognitive disease. Nat. Cell Biol. 2008, 455, 903–911. [CrossRef]
130. Kirov, G.; Rujescu, D.; Ingason, A.; Collier, D.A.; O’Donovan, M.; Owen, M.J. Neurexin 1 (NRXN1) Deletions in Schizophrenia.
Schizophr. Bull. 2009, 35, 851–854. [CrossRef]
131. Rujescu, D.; Ingason, A.; Cichon, S.; Pietiläinen, O.P.; Barnes, M.; Toulopoulou, T.; Picchioni, M.; Vassos, E.; Ettinger, U.; Bramon,
E.; et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 2008, 18, 988–996. [CrossRef]
132. Mulle, J.G.; Dodd, A.F.; McGrath, J.A.; Wolyniec, P.S.; Mitchell, A.A.; Shetty, A.; Sobreira, N.L.; Valle, D.; Rudd, M.K.; Satten, G.;
et al. Microdeletions of 3q29 Confer High Risk for Schizophrenia. Am. J. Hum. Genet. 2010, 87, 229–236. [CrossRef]
133. Tordjman, S.; Anderson, G.M.; Botbol, M.; Toutain, A.; Sarda, P.; Carlier, M.; Saugier-Veber, P.; Baumann, C.; Cohen, D.; Lagneaux,
C.; et al. Autistic Disorder in Patients with Williams-Beuren Syndrome: A Reconsideration of the Williams-Beuren Syndrome
Phenotype. PLoS ONE 2012, 7, e30778. [CrossRef]
134. Tordjman, S.; Anderson, G.M.; Cohen, D.; Kermarrec, S.; Carlier, M.; Touitou, Y.; Saugier-Veber, P.; Lagneaux, C.; Chevreuil, C.;
Verloes, A. Presence of autism, hyperserotonemia, and severe expressive language impairment in Williams-Beuren syndrome.
Mol. Autism 2013, 4, 29. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 9464 21 of 22
135. Tordjman, S.; Somogyi, E.; Coulon, N.; Kermarrec, S.; Cohen, D.; Bronsard, G.; Bonnot, O.; Weismann-Arcache, C.; Botbol, M.;
Lauth, B.; et al. Gene x environment interactions in autism spectrum disorders: Role of epigenetic mechanisms. Front. Psychiatry
2014, 5, 1–17. [CrossRef]
136. Mervis, C.B.; Dida, J.; Lam, E.; Crawford-Zelli, N.A.; Young, E.J.; Henderson, D.R.; Onay, T.; Morris, C.A.; Woodruff-Borden,
J.; Yeomans, J.; et al. Duplication of GTF2I Results in Separation Anxiety in Mice and Humans. Am. J. Hum. Genet. 2012, 90,
1064–1070. [CrossRef]
137. Tordjman, S.; Celume, M.; Denis, L.; Motillon, T.; Keromnes, G. Reframing schizophrenia and autism as bodily self-consciousness
disorders leading to a deficit of theory of mind and empathy with social communication impairments. Neurosci. Biobehav. Rev.
2019, 103, 401–413. [CrossRef]
138. Ben-Shachar, S.; Ou, Z.; Shaw, C.; Belmont, J.; Patel, M.; Hummel, M.; Amato, S.; Tartaglia, N.; Berg, J.; Sutton, V.R.; et al. 22q11.2
Distal Deletion: A Recurrent Genomic Disorder Distinct from DiGeorge Syndrome and Velocardiofacial Syndrome. Am. J. Hum.
Genet. 2008, 82, 214–221. [CrossRef] [PubMed]
139. von der Lippe, C.; Rustad, C.; Heimdal, K.; Rødningen, O. 15q11.2 microdeletion—Seven new patients with delayed development
and/or behavioural problems. Eur. J. Med Genet. 2011, 54, 357–360. [CrossRef]
140. Stefansson, H.; Meyer-Lindenberg, A.; Steinberg, S.; Magnusdottir, B.B.; Morgen, K.; Arnarsdottir, S.; Bjornsdottir, G.; Walters,
G.B.; Jonsdottir, G.A.; Doyle, O.; et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nat. Cell Biol.
2013, 505, 361–366. [CrossRef]
141. Kumar, R.A.; KaraMohamed, S.; Sudi, J.; Conrad, D.F.; Brune, C.; Badner, J.A.; Gilliam, T.C.; Nowak, N.J.; Cook, E.H., Jr.; Dobyns,
W.B.; et al. Recurrent 16p11.2 microdeletions in autism. Hum. Molec. Genet. 2008, 17, 628–638. [CrossRef]
142. Itsara, A.; Cooper, G.M.; Baker, C.; Girirajan, S.; Li, J.; Absher, D.; Krauss, R.M.; Myers, R.M.; Ridker, P.M.; Chasman, D.I.; et al.
Population Analysis of Large Copy Number Variants and Hotspots of Human Genetic Disease. Am. J. Hum. Genet. 2009, 84,
148–161. [CrossRef]
143. Kirov, G.; Pocklington, A.; Holmans, P.; Ivanov, D.; Ikeda, M.; Ruderfer, D.; Moran, J.; Chambert, K.; Toncheva, D.; Georgieva,
L.; et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of
schizophrenia. Mol. Psychiatry 2011, 17, 142–153. [CrossRef]
144. Yang, A.C.; Tsai, S.-J. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. Int. J. Mol. Sci. 2017, 18, 1689.
[CrossRef]
145. Pardiñas, A.F.; Holmans, P.; Pocklington, A.; Escott-Price, V.; Ripke, S.; Carrera, N.; Legge, S.E.; Bishop, S.; Cameron, D.; Hamshere,
M.L.; et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background
selection. Nat. Genet. 2018, 50, 381–389. [CrossRef]
146. Amiet, C.; Gourfinkel-An, I.; Laurent, C.; Bodeau, N.; Génin, B.; Leguen, E.; Tordjman, S.; Cohen, D. Does epilepsy in multiplex
autism pedigrees define a different subgroup in terms of clinical characteristics and genetic risk? Mol. Autism 2013, 4, 1–16.
[CrossRef]
147. Do, K.Q.; Trabesinger, A.; Kirsten-Krüger, M.; Lauer, C.J.; Dydak, U.; Hell, D.; Holsboer, F.; Boesiger, P.; Cuénod, M. Schizophrenia:
Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000, 12, 3721–3728. [CrossRef]
148. Lacy, N.; King, B.H. Revisiting the relationship between autism and schizophrenia: Toward an integrated neurobiology. Annu.
Rev. Clin. Psychol. 2013, 9, 555–587. [CrossRef]
149. Malhotra, D.; Sebat, J. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. Cell 2012, 148, 1223–1241.
[CrossRef]
150. Porokhovnik, L.N.; Lyapunova, N.A. Dosage effects of human ribosomal genes (rDNA) in health and disease. Chromosom. Res.
2018, 27, 5–17. [CrossRef]
151. Chestkov, I.; Jestkova, E.; Ershova, E.; Golimbet, V.; Lezheiko, T.; Kolesina, N.; Porokhovnik, L.; Lyapunova, N.; Izhevskaya, V.;
Kutsev, S.; et al. Abundance of ribosomal RNA gene copies in the genomes of schizophrenia patients. Schizophr. Res. 2018, 197,
305–314. [CrossRef]
152. Oken, R.J.; Schulzer, M. At Issue: Schizophrenia and Rheumatoid Arthritis: The Negative Association Revisited. Schizophr. Bull.
1999, 25, 625–638. [CrossRef]
153. Gorwood, P.; Pouchot, J.; Vinceneux, P.; Puéchal, X.; Flipo, R.; De Bandt, M.; Adès, J. Rheumatoid arthritis and schizophrenia: A
negative association at a dimensional level. Schizophr. Res. 2004, 66, 21–29. [CrossRef]
154. Porokhovnik, L. Individual Copy Number of Ribosomal Genes as a Factor of Mental Retardation and Autism Risk and Severity.
Cells 2019, 8, 1151. [CrossRef]
155. Ershova, E.S.; Agafonova, O.N.; Zakharova, N.; Bravve, L.V.; Jestkova, E.M.; Golimbet, V.E.; Lezheiko, T.V.; Morozova, A.Y.;
Martynov, A.V.; Veiko, R.V.; et al. Copy Number Variation of Satellite III (1q12) in Patients with Schizophrenia. Front. Genet.
2019, 10. [CrossRef]
156. International Schizophrenia Consortium; Purcell, S.M.; Wray, N.R.; Stone, J.L.; Visscher, P.M.; O’Donovan, M.C.; Sullivan, P.F.;
Sklar, P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460, 748–752.
[CrossRef]
157. Mistry, S.; Harrison, J.; Smith, D.; Escott-Price, V.; Zammit, S. The use of polygenic risk scores to identify phenotypes associated
with genetic risk of schizophrenia: Systematic review. Schizophr. Res. 2018, 197, 2–8. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 9464 22 of 22
158. Coulon, N.; Brailly-Tabard, S.; Walter, M.; Tordjman, S. Altered circadian patterns of salivary cortisol in individuals with
schizophrenia: A critical literature review. J. Physiol. 2016, 110, 439–447. [CrossRef]
159. Tordjman, S.; Anderson, G.M.; Kermarrec, S.; Bonnot, O.; Geoffray, M.-M.; Brailly-Tabard, S.; Chaouch, A.; Colliot, I.; Trabado,
S.; Bronsard, G.; et al. Altered circadian patterns of salivary cortisol in low-functioning children and adolescents with autism.
Psychoneuroendocrinology 2014, 50, 227–245. [CrossRef]
160. Le Roy, I.; Roubertoux, P.L.; Jamot, L.; Maarouf, F.; Tordjman, S.; Mortaud, S.; Blanchard, C.; Martin, B.; Guillot, P.V.; Duquenne, V.
Neuronal and behavioral differences between Mus musculus domesticus (C57BL/6JBy) and Mus musculus castaneus (CAST/Ei).
Behav. Brain Res. 1998, 95, 135–142. [CrossRef]
161. Tordjman, S.; Drapier, D.; Bonnot, O.; Graignic, R.; Fortes, S.; Cohen, D.; Millet, B.; Laurent, C.; Roubertoux, P.L. Animal Models
Relevant to Schizophrenia and Autism: Validity and Limitations. Behav. Genet. 2006, 37, 61–78. [CrossRef]
162. Do, K.Q. Schizophrenia: Genes, environment and neurodevelopment. Rev. Med. Suisse 2013, 9, 1674–1677.
163. Janssen, I.; Krabbendam, L.; Bak, M.; Hanssen, M.; Vollebergh, W.; De Graaf, R.; Van Os, J. Childhood abuse as a risk factor for
psychotic experiences. Acta Psychiatr. Scand. 2004, 109, 38–45. [CrossRef] [PubMed]
164. Gourion, D.; Gourevitch, R.; Le Provost, J.-B.; Olié, J.-P.; Lôo, H.; Krebs, M.-O. Neurodevelopmental hypothesis in schizophrenia.
Encephale 2004, 30, 109–118. [CrossRef]
165. McGrath, J.; El-Saadi, O.; Grim, V.; Cardy, S.; Chapple, B.; Chant, D.; Lieberman, D.; Mowry, B. Minor Physical Anomalies and
Quantitative Measures of the Head and Face in Patients with Psychosis. Arch. Gen. Psychiatry 2002, 59, 458–464. [CrossRef]
166. Mhalla, A.; Boussaïd, N.; Gassab, L.; Gaha, L.; Mechri, A. Minor neurological and physical anomalies in patients with first-episode
psychosis. Encéphale 2013, 39, 149–154. [CrossRef]
167. Weinberg, S.M.; Jenkins, E.A.; Marazita, M.L.; Maher, B.S. Minor physical anomalies in schizophrenia: A meta-analysis. Schizophr.
Res. 2007, 89, 72–85. [CrossRef]
168. Schiffman, J.; Ekstrom, M.; Labrie, J.; Schulsinger, F.; Sorensen, H.; Mednick, S. Minor Physical Anomalies and Schizophrenia
Spectrum Disorders: A Prospective Investigation. Am. J. Psychiatry 2002, 159, 238–243. [CrossRef]
169. Green, M.F.; Satz, P.; Gaier, D.J.; Ganzell, S.; Kharabi, F. Minor Physical Anomalies in Schizophrenia. Schizophr. Bull. 1989, 15,
91–99. [CrossRef] [PubMed]
170. Missaoui, S.; Mechri, A.; Gaddour, N.; Slama, H.; Gaha, L. La schizophrénie à début précoce: Caractéristiques cliniques et
endophénotypiques. Ann. Med. Psychol. Rev. Psychiatr. 2008, 166, 633–637. [CrossRef]
171. Franco, J.G.; Valero, J.; Labad, A. Minor physical anomalies and schizophrenia: Literature review. Actas Espanolas Psiquiatr. 2010,
38, 365–371.
172. Lewis, S.W. Psychopathology and brain dysfunction: Structural imaging studies. In Neurodevelopment and Adult Psychopathology;
Keshavan, M., Murray, R.M., Eds.; Cambridge University Press: Cambridge, UK, 1997; pp. 178–186.
173. Shenton, M.E.; Kubicki, M. Structural brain imaging in schizophrenia. In Kaplan and Sadock’s Comprehensive Textbook of Psychiatry,
9th ed.; Sadock, B.J., Sadock, V.A., Ruiz, P., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2009; pp. 1497–1507.
174. Wilczynska, K.; Wojcik, M.; Rozenek, E.B.; Zalewski, D.; Stapinski, P.; Maciejczyk, M.; Waszkiewicz, N. Morphological changes of
the brain in schizophrenia. Przegl Lekarski 2019, 76, 574–577.
175. Herold, C.J.; Essig, M.; Schröder, J. Neurological soft signs (NSS) and brain morphology in patients with chronic schizophrenia
and healthy controls. PLoS ONE 2020, 15, e0231669. [CrossRef]
176. Gurovich, Y.; Hanani, Y.; Bar, O.; Nadav, G.; Fleischer, N.; Gelbman, D.; Gripp, K.W. Identifying facial phenotypes of genetic
disorders using deep learning. Nat. Med. 2019, 25, 60–64. [CrossRef]
